Mark Kozinn
Neurology · Riverdale, GANPI 1184696973
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.2% of the total across 144 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 16.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $924 and has fallen 96.0% since, to $37 in 2023.
Across 144 payments — averaging $17.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$412
- Upsher-smith Laboratories LLC$244
- Sanofi$168
- AstraZeneca$155
- EMD Serono, Inc.$144
- UCB, Inc.$143
- plus $1K from 30 others
What the payments were for
- Food & beverage$2,43795%
- Education$1245%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 25 | $412 |
| Upsher-smith Laboratories LLC | 23 | $244 |
| Sanofi | 8 | $168 |
| AstraZeneca(2 entities) | 7 | $155 |
| EMD Serono, Inc. | 8 | $144 |
| UCB, Inc. | 6 | $143 |
| SK Life Science, Inc. | 3 | $136 |
| Amgen(2 entities) | 7 | $114 |
| GE HealthCare | 4 | $84 |
| Teva Pharmaceuticals USA, Inc. | 5 | $79 |
| Biohaven Pharmaceuticals, Inc. | 4 | $70 |
| Kyowa Kirin, Inc. | 5 | $68 |
| Biogen | 3 | $63 |
| Lundbeck LLC | 3 | $63 |
| CSL Behring | 2 | $58 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $57 |
| Johnson & Johnson | 2 | $52 |
| Grifols USA, LLC | 3 | $45 |
| Acadia Pharmaceuticals Inc | 2 | $34 |
| Neurelis, Inc. | 2 | $34 |
| Bristol Myers Squibb | 2 | $32 |
| Amneal Pharmaceuticals LLC | 1 | $31 |
| Vertical Pharmaceuticals, LLC | 2 | $27 |
| Boehringer Ingelheim | 2 | $25 |
| Adamas Pharmaceuticals, Inc. | 1 | $23 |
| Aprecia Pharmaceuticals, LLC | 1 | $23 |
| Argenx US, Inc. | 1 | $22 |
| Livanova USA, Inc. | 1 | $22 |
| Genentech USA, Inc. | 1 | $21 |
| Jazz Pharmaceuticals Inc. | 1 | $21 |
| Greenwich Biosciences, Inc. | 1 | $20 |
| Impel Pharmaceuticals Inc. | 1 | $18 |
| Pfizer | 1 | $15 |
| Lilly USA, LLC | 1 | $14 |
| United Therapeutics Corporation | 1 | $12 |
| Advanced Respiratory, Inc | 1 | $11 |
How this compares
$2,560 in reported general payments places this provider in the 55th percentile of 506 neurology providers in Georgia.
Other neurology in Riverdale
- Mitzi WilliamsSmyrna$1.4M
- Joash LazarusAtlanta$1.1M
- Jeffrey EnglishAtlanta$749K
- John MorganAugusta$715K
- Frank BerensonAtlanta$527K
- Julio FlaminiAtlanta$501K
- Douglas StuartAtlanta$493K
- Sudhir AthniMacon$432K
- Dinesh RajuLawrenceville$414K
- Victor RosenfeldSavannah$413K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.